Five-fraction SRBT schedule well tolerated with high tumor-control rate in central lung cancersApril 9, 2019Lung Cancer
Antibiotics gut checkpoint inhibitor efficacyMarch 12, 2019Immuno-oncologyHead & Neck/Thyroid CancersLung CancerMelanoma
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLCMarch 7, 2019Lung CancerImmuno-oncologyImmunotherapy
FDA Expanded Access benefits heavily pretreated patients, especially childrenMarch 4, 2019Practice ManagementCNS/Brain CancerBreast CancerLung Cancer
NILE: Liquid biopsy bests tissue testing for targetable mutations in NSCLCFebruary 28, 2019Lung Cancer
Caring for aging HIV-infected patients requires close attention to unrelated diseasesFebruary 27, 2019Lung CancerMixed Topics
Checkpoint inhibitors ‘viable treatment option’ in HIV-infected individualsFebruary 8, 2019Immuno-oncologyLung CancerSarcoma & GISTMelanoma
Enoblituzumab plus pembrolizumab shows promise for select solid tumorsFebruary 7, 2019Lung CancerImmuno-oncologyHead & Neck/Thyroid Cancers
Lifetime cost of tobacco use tops $1.9 million per smokerFebruary 1, 2019Lung CancerPractice ManagementPreventive Care
